V
53.16
-1.55 (-2.83%)
| Previous Close | 54.71 |
| Open | 54.72 |
| Volume | 995,888 |
| Avg. Volume (3M) | 1,359,405 |
| Market Cap | 7,719,164,416 |
| Price / Book | 3.26 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Diluted EPS (TTM) | -3.99 |
| Total Debt/Equity (MRQ) | 2.72% |
| Current Ratio (MRQ) | 17.70 |
| Operating Cash Flow (TTM) | -459.78 M |
| Levered Free Cash Flow (TTM) | -419.13 M |
| Return on Assets (TTM) | -14.53% |
| Return on Equity (TTM) | -19.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Vaxcyte, Inc. | Bullish | Bearish |
AIStockmoo Score
1.7
| Analyst Consensus | 5.0 |
| Insider Activity | -2.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.70 |
|
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.68% |
| % Held by Institutions | 117.40% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 116.00 (Guggenheim, 118.21%) | Buy |
| Median | 102.50 (92.81%) | |
| Low | 89.00 (BTIG, 67.42%) | Buy |
| Average | 102.50 (92.81%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 58.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 26 Feb 2026 | 89.00 (67.42%) | Buy | 60.00 |
| Guggenheim | 02 Feb 2026 | 116.00 (118.21%) | Buy | 57.40 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COWAN ELVIA | - | 60.69 | -3,000 | -182,070 |
| Aggregate Net Quantity | -3,000 | |||
| Aggregate Net Value ($) | -182,070 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 60.69 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COWAN ELVIA | Officer | 07 Apr 2026 | Automatic sell (-) | 3,000 | 60.69 | 182,070 |
| COWAN ELVIA | Officer | 07 Apr 2026 | Option execute | 3,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit |
| 02 Feb 2026 | Announcement | Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares |
| 29 Jan 2026 | Announcement | Vaxcyte Announces Pricing of $550 Million Public Offering |
| 29 Jan 2026 | Announcement | Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants |
| 22 Jan 2026 | Announcement | Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |